NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, AUSTRALIA, BELARUS, CANADA, HONGKONG, JAPAN, NEW ZEALAND, RUSSIA, SINGAPORE, SOUTH AFRICA OR SWITZERLAND, OR ANY OTHER JURISDICTION IN WHICH THE PUBLICATION, DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL OR REQUIRE REGISTRATION OR ANY OTHER MEASURES. PLEASE SEE IMPORTANT INFORMATION AT THE END OF THIS PRESS RELEASE.

Notice of stabilisation measures and termination of stabilisation period

ABG Sundal Collier AB ("ABG"), in its capacity as Joint Global Coordinator and stabilization manager, notifies that the overallotment option in connection with Meds Apotek AB (publ) ("MEDS" or the "Company") offering of shares prior to the listing on Nasdaq First North Premier Growth Market (the "Offering") has not been exercised. The stabilisation period has now ended and no further stabilisation measures will be conducted.

As announced in connection with the Offering, ABG had the option, acting as Joint Global Coordinator and stabilisation manager, to carry out transactions aimed at supporting the market price of the shares at levels above those which might otherwise have prevailed in the market. Stabilisation transactions could have been undertaken on Nasdaq First North Premier Growth Market, in the over-the-counter market or otherwise, at any time during the period from the date of commencement of trading in the shares on Nasdaq First North Premier Growth Market, 23 September 2025, and ending no later than 30 calendar days thereafter. However, ABG had no obligation to undertake any stabilisation measures. Transactions have not been conducted at a price higher than set out in the Offering, i.e. SEK 53.

The company granted the Joint Global Coordinators an over-allotment option which was managed by ABG and could have been utilised in whole or in part for 30 days from the first day of trading of the Company's shares on Nasdaq First North Premier Growth Market to be able to sell up to 622,641 shares corresponding to up to 15 percent of the total number of shares in the Offering to cover any over-allotment in connection with the Offering (the "**Over-allotment Option**").

ABG now announces that the Over-allotment Option has not been exercised and consequently that 622,641 shares in MEDS, which ABG has borrowed from M2 Asset Management AB in order to cover any over-allotment in connection with the Offering, will be returned shortly. The stabilisation period in the Offering has now ended and no further stabilisation transactions will be conducted. ABG announces, in its capacity as Joint Global Coordinator and stabilisation manager, that stabilisation measures have been undertaken in accordance with article 5(4) in the EU Market Abuse Regulation 596/2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052 as specified below.

The contact person at ABG is Erik Skog (tel: +46 8 566 29 471, e-post: **Erik.Skog@abgsc.se**).

Stabilisation information:

Issuer:	Meds Apotek AB (publ)
Securities:	Ordinary shares (ISIN: SE0018014110)
Offering size:	4,150,942 shares
Over-allotment option:	622,641 shares
Offer price:	53 SEK
Market:	Nasdaq First North Premier Growth Market
Ticker:	MEDS
Stabilisation manager:	ABG Sundal Collier AB

Stabilisation transactions:

Date	***Quantity, shares***	***Price (highest)***	***Price (lowest)***	***Price (volume weighted average)***	***Curr-ency***	***Trading venue***
29 September 2025	64,897	53.00	53.00	53.00	SEK	Nasdaq First North Premier Growth Market
7 October 2025	15,000	53.00	53.00	53.00	SEK	Nasdaq First North Premier Growth Market
8 October 2025	15,000	53.00	53.00	53.00	SEK	Nasdaq First North Premier Growth Market
9 October 2025	90,982	53.00	53.00	53.00	SEK	Nasdaq First North Premier Growth Market
10 October 2025	94,344	53.00	53.00	53.00	SEK	Nasdaq First North Premier Growth Market
13 October 2025	103,479	53.00	53.00	53.00	SEK	Nasdaq First North Premier Growth Market
14 October 2025	58,807	53.00	53.00	53.00	SEK	Nasdaq First North Premier Growth Market
15 October 2025	16,382	53.00	53.00	53.00	SEK	Nasdaq First North Premier Growth Market

16 October 2025	8,750	53.00	53.00	53.00	SEK	Nasdaq First North Premier Growth Market
17 October 2025	24,610	53.00	52.50	52.99	SEK	Nasdaq First North Premier Growth Market
21 October 2025	24,213	53.00	53.00	53.00	SEK	Nasdaq First North Premier Growth Market
22 October 2025	9,428	53.00	53.00	53.00	SEK	Nasdaq First North Premier Growth Market
23 October 2025	96,749	53.00	51.50	52.65	SEK	Nasdaq First North Premier Growth Market

FNCA Sweden AB is the Company's Certified Adviser and can be reached by telephone at +46 (0)8 528 00 399 and by email at **info@fnca.se**.

For further information, please contact:
Björn Thorngren, CEO and founder, e-mail: **bjorn@meds.se**

Press contact, e-mail: **press@meds.se**, telephone: +46 72-141 73 28

This information is information that MEDS is obliged to make public pursuant to the EU Market Abuse Regulation 596/2014. The information in this press release has been made public through the agency of the contact person set out above, at 21:10 CEST on 23 October 2025.

About MEDS

MEDS, launched in 2018, is a full-scale online pharmacy operating in the Swedish outpatient market. The Company offers its customers an extensive product range at attractive prices. The Company is licensed by the Swedish Medical Products Agency, the National Food Agency, and the eHealth Agency, and offers its customers prescription medications, over-the-counter medications, and a wide selection of commercial goods such as beauty products, dietary supplements, children's products, fitness products, food and drinks, and home & household products. As of 30 June 2025, the Company had approximately 960,000 active customers[1] and always strives to deliver goods directly, quickly and reliably. MEDS experienced a net sales growth of 27% in 2024, and the Company's net sales for the last twelve months as of 30 June 2025 amounted to approximately SEK 928 million. The Company has been profitable at an adjusted EBIT level since Q4 2024, where MEDS during H1 2025 achieved an adjusted EBIT margin of 2.0 percent. The Company's headquarters is located in Stockholm, and as of 30 June 2025, the number of employees was 51.

Important information

The information in this press release does not contain or constitute an offer to acquire, subscribe for, or otherwise trade in securities in MEDS.

The release, announcement or distribution of this press release may, in certain jurisdictions, be subject to restrictions and the recipients of this press release in jurisdictions where this press release has been published or distributed shall inform themselves of and follow such legal restrictions. The recipient of this press release is responsible for using this press release, and the information contained herein, in accordance with applicable rules in each jurisdiction. This press release does not constitute an offer, or a solicitation of any offer, to buy or subscribe for any securities in the Company in any jurisdiction, neither from the Company nor from anyone else.

This press release does not constitute or form part of an offer or solicitation to purchase or subscribe for securities in the United States. The securities referred to herein may not be sold in the United States absent registration or an exemption from registration under the US Securities Act of 1933, as amended (the "**Securities Act**"), and may not be offered or sold within the United States absent registration or an applicable exemption from, or in a transaction not subject to, the registration requirements of the Securities Act. There is no intention to register any securities referred to herein in the United States or to make a public offering of the securities in the United States. The information in this press release may not be announced, published, copied, reproduced or distributed, directly or indirectly, in whole or in part, within or into the United States, Australia, Belarus, Canada, Hong Kong, Japan, New Zealand, Russia, Singapore, South Africa or Switzerland or in any other jurisdiction where such announcement, publication or distribution of the information would not comply with applicable laws and regulations or where such actions are subject to legal restrictions or would require additional registration or other measures than what is required under Swedish law. Actions taken in violation of this instruction may constitute a crime against applicable securities laws and regulations.

This press release is not a prospectus for the purposes of Regulation (EU) 2017/1129 (the "**Prospectus Regulation**") and has not been approved by any regulatory authority in any jurisdiction. A prospectus has been prepared and published by the Company in connection with the Listing. This prospectus has been reviewed and approved by the SFSA, which is the national competent authority in Sweden under the Prospectus Regulation. Investors should not invest in the securities described in this press release based on anything other than the information in the prospectus that the Company has published in connection with the Listing.

In the United Kingdom, this press release and any other materials in relation to the securities described herein is only being distributed to, and is only directed at, and any investment or investment activity to which this document relates is available only to, and will be engaged in only with, "qualified investors" (within the meaning of the United Kingdom version of the EU Prospectus Regulation (2017/1129/ EU) which is part of United Kingdom law by virtue of the European Union (Withdrawal) Act 2018) who are (i) persons having professional experience in matters relating to investments who fall within the definition of "investment professionals" in Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (the "**Order**"); or (ii) high net worth entities falling within Article 49(2)(a) to (d) of the Order (all such persons together being referred to as "relevant persons"). In the United Kingdom, any investment or investment activity to which this communication relates is available only to, and will be engaged in only with, relevant persons. Persons who are not relevant persons should not take any action on the basis of this press release and should not act or rely on it.

This press release does not identify or suggest, or purport to identify or suggest, the risks (direct or indirect) that may be associated with an investment in the new securities. Any investment decision to acquire or subscribe for securities in connection with the Offering must be made on the basis of all publicly available information relating to the Company and the Company's securities. Such information has not been independently verified by Joint Global Coordinators and Joint Bookrunners. Joint Global Coordinators and Joint Bookrunners are acting for the Company in connection with the transaction and no one else and will not be responsible to anyone other than the Company for providing the protections afforded to its clients nor for giving advice in relation to the transaction or any other matter referred to herein.

The information in this press release may not be forwarded or distributed to any other person and may not be reproduced at all. Any forwarding, distribution, reproduction or disclosure of this information in its entirety or in any part is prohibited. Failure to follow these instructions may result in a breach of the Securities Act or applicable laws in other jurisdictions.

This press release does not constitute an invitation to warrant, subscribe, or otherwise acquire or transfer any securities in any jurisdiction. This press release does not constitute a recommendation for any investors' decisions regarding the Offering. Each investor or potential investor should conduct a self-examination, analysis and evaluation of the business and information described in this press release and any publicly available information. The price and value of the securities can decrease as well as increase. Achieved results do not provide guidance for future results. Neither the contents of the Company's website nor any other website accessible through hyperlinks on the Company's website are incorporated into or form part of this press release.

[1] Active customer - a person who has made at least one purchase in the past twelve months.

This information is information that MEDS Apotek AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 2025-10-23 21:10 CEST.

Attachments

Notice of stabilisation measures and termination of stabilisation period